Trinity Biotech (TRIB) Receivables (2016 - 2024)
Trinity Biotech (TRIB) has disclosed Receivables for 9 consecutive years, with $1.2 million as the latest value for Q4 2024.
- Quarterly Receivables fell 99.95% to $1.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2024, down 99.95% year-over-year, with the annual reading at $1.2 million for FY2024, 99.95% down from the prior year.
- Receivables hit $1.2 million in Q4 2024 for Trinity Biotech, down from $2.3 billion in the prior quarter.
- In the past five years, Receivables ranged from a high of $2.7 billion in Q4 2022 to a low of $1.2 million in Q4 2024.
- Historically, Receivables has averaged $1.0 billion across 5 years, with a median of $3.9 million in 2020.
- Biggest five-year swings in Receivables: soared 90020.56% in 2022 and later tumbled 99.95% in 2024.
- Year by year, Receivables stood at $3.9 million in 2020, then decreased by 23.87% to $3.0 million in 2021, then skyrocketed by 90020.56% to $2.7 billion in 2022, then fell by 13.63% to $2.3 billion in 2023, then crashed by 99.95% to $1.2 million in 2024.
- Business Quant data shows Receivables for TRIB at $1.2 million in Q4 2024, $2.3 billion in Q4 2023, and $2.7 billion in Q4 2022.